RRA
CPRX

Round Rock Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Round Rock Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Hold
32,438
– – 0.13% 119
2026
Q1 		$803K Buy
32,438
+81
+0.3% +$1.93K 0.12% 131
2025
Q4 		$755K Buy
32,357
+7,247
+29% +$161K 0.11% 143
2025
Q3 		$497K Buy
+25,110
New +$516K 0.08% 175

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Round Rock Advisors's CPRX Position: Q2 2026 in Review

Round Rock Advisors held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 32,438 shares worth $1.02M. The position accounts for 0.13% of the portfolio, ranked #119.

Round Rock Advisors first reported a position in CPRX in Q3 2025 and has held it in 4 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Round Rock Advisors held 32,438 shares of Catalyst Pharmaceutical worth $1.02M as of Q2 2026.
  • Round Rock Advisors left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
  • Catalyst Pharmaceutical made up 0.13% of Round Rock Advisors's portfolio in Q2 2026, its #119 holding.
  • Round Rock Advisors first reported a position in Catalyst Pharmaceutical in Q3 2025 and has held it in 4 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Round Rock Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.